These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 3975648)

  • 21. Endometrial hyperplasia treated by progestins.
    Eichner E; Abellera M
    Obstet Gynecol; 1971 Nov; 38(5):739-42. PubMed ID: 5114224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer.
    Wu HM; Lai CH; Huang HY; Wang HS; Soong YK
    Chang Gung Med J; 2008; 31(1):102-6. PubMed ID: 18419059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Young women with atypical endometrial hyperplasia or endometrial adenocarcinoma stage I: will conservative treatment allow pregnancy? Results of a French multicentric survey].
    Le Digabel JF; Gariel C; Catala L; Dhainaut C; Madelenat P; Descamps P
    Gynecol Obstet Fertil; 2006 Jan; 34(1):27-33. PubMed ID: 16406735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of progestational agents in treatment of endometrial carcinoma.
    Podratz KC; O'Brien PC; Malkasian GD; Decker DG; Jefferies JA; Edmonson JH
    Obstet Gynecol; 1985 Jul; 66(1):106-10. PubMed ID: 4011061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.
    Ramirez PT; Frumovitz M; Bodurka DC; Sun CC; Levenback C
    Gynecol Oncol; 2004 Oct; 95(1):133-8. PubMed ID: 15385122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
    Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
    Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effective progestogen therapy of endometrial hyperplasia and adenocarcinoma by administration of a combined progestogen-estrogen preparation].
    Miyawaki Y; Ueki M; Sugimoto O
    Nihon Gan Chiryo Gakkai Shi; 1988 Oct; 23(10):2598-605. PubMed ID: 3209928
    [No Abstract]   [Full Text] [Related]  

  • 28. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications.
    Ehrlich CE; Young PC; Cleary RE
    Am J Obstet Gynecol; 1981 Nov; 141(5):539-46. PubMed ID: 6457531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy with gestagens for gynecological tumors sensitive to hormones (author's transl)].
    Weghaupt K
    Strahlentherapie; 1979 Oct; 155(10):690-3. PubMed ID: 91247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of progestins on the ultrastructure of endometrial cells in pretumorous changes and cancer (an organ-culture study)].
    Beliaeva LA; Bukhvalov IB; Zheleznov BI; Raĭkhlin NT
    Arkh Patol; 1982; 44(4):18-25. PubMed ID: 7082195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uterine adenocarcinoma metastatic to the skin responsive to megestrol acetate.
    Spencer DM; Bigler LR; Wilkin JK; Gams RA
    J Dermatol Surg Oncol; 1994 Aug; 20(8):544-7. PubMed ID: 8056889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
    Rubatt JM; Slomovitz BM; Burke TW; Broaddus RR
    Gynecol Oncol; 2005 Nov; 99(2):472-6. PubMed ID: 16099019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer.
    Yang YC; Wu CC; Chen CP; Chang CL; Wang KL
    Gynecol Oncol; 2005 Nov; 99(2):287-93. PubMed ID: 16051341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study.
    Rattanachaiyanont M; Angsuwathana S; Techatrisak K; Tanmahasamut P; Indhavivadhana S; Leerasiri P
    J Obstet Gynaecol Res; 2005 Apr; 31(2):98-106. PubMed ID: 15771634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
    Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
    Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steroid receptors in endolymphatic stromal myosis.
    Baker VV; Walton LA; Fowler WC; Currie JL
    Obstet Gynecol; 1984 Mar; 63(3 Suppl):72S-74S. PubMed ID: 6700885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occult myometrial recurrence after progesterone therapy to preserve fertility in a young patient with endometrial cancer.
    Hurst SA; Hartzfeld KM; Del Priore G
    Fertil Steril; 2008 Mar; 89(3):724.e1-3. PubMed ID: 17570366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.
    Morgan LR
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):43-7. PubMed ID: 3975652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
    Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjunctive and therapeutic progestins in endometrial cancer.
    Kneale BL
    Clin Obstet Gynaecol; 1986 Dec; 13(4):789-809. PubMed ID: 3641697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.